Bristol-Myers Squibb Co (NYSE:BMY) declared a quarterly dividend on Thursday, June 14th, RTT News reports. Stockholders of record on Friday, July 6th will be given a dividend of 0.40 per share by the biopharmaceutical company on Wednesday, August 1st. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.89%. The ex-dividend date is Thursday, July 5th.
Bristol-Myers Squibb has increased its dividend by an average of 2.7% annually over the last three years and has raised its dividend annually for the last 8 consecutive years. Bristol-Myers Squibb has a payout ratio of 53.5% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Bristol-Myers Squibb to earn $3.65 per share next year, which means the company should continue to be able to cover its $1.60 annual dividend with an expected future payout ratio of 43.8%.
Bristol-Myers Squibb stock opened at $55.34 on Friday. Bristol-Myers Squibb has a twelve month low of $49.96 and a twelve month high of $70.05. The company has a market cap of $90.39 billion, a PE ratio of 18.39, a P/E/G ratio of 1.45 and a beta of 0.95. The company has a quick ratio of 1.39, a current ratio of 1.52 and a debt-to-equity ratio of 0.45.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 26th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.09. Bristol-Myers Squibb had a net margin of 4.37% and a return on equity of 37.56%. The firm had revenue of $5.19 billion during the quarter, compared to the consensus estimate of $5.25 billion. During the same period in the prior year, the firm earned $0.84 EPS. The company’s revenue was up 5.4% compared to the same quarter last year. equities analysts expect that Bristol-Myers Squibb will post 3.42 EPS for the current fiscal year.
A number of research analysts have recently weighed in on BMY shares. Bank of America increased their target price on shares of Bristol-Myers Squibb from $64.00 to $68.00 and gave the company a “neutral” rating in a research report on Monday, March 5th. ValuEngine cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, March 7th. TheStreet cut shares of Bristol-Myers Squibb from a “b” rating to a “c+” rating in a research note on Thursday, March 8th. JPMorgan Chase & Co. set a $75.00 price target on shares of Bristol-Myers Squibb and gave the company an “overweight” rating in a research note on Tuesday, March 20th. Finally, Argus dropped their price target on shares of Bristol-Myers Squibb from $75.00 to $66.43 and set a “buy” rating on the stock in a research note on Wednesday, March 21st. Three research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and seven have issued a buy rating to the stock. Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus target price of $62.84.
In other news, Director Dinesh C. Paliwal bought 4,770 shares of the stock in a transaction on Monday, April 30th. The shares were acquired at an average cost of $52.40 per share, for a total transaction of $249,948.00. Following the purchase, the director now directly owns 8,027 shares of the company’s stock, valued at approximately $420,614.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.